Caricamento...
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for CML patients and exert a dual mode of action:...
Salvato in:
| Pubblicato in: | Front Immunol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5402174/ https://ncbi.nlm.nih.gov/pubmed/28484463 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00469 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|